02519nam 2200493 450 991071734570332120221104205458.0(CKB)2670000000429444(NjHacI)992670000000429444(OCoLC)793073726(OCoLC)1117847271(EXLCZ)99267000000042944420221104d2011 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierTreatment of anemia in patients with heart disease a systematic review /Devan Kansagara [and four others]Washington, DC :Department of Veterans Affairs,2011.1 online resource (iii, 78 pages) illustrationsEvidence-based Synthesis Program"Evidence-based synthesis program.""October 2011."Includes bibliographical references.Anemia is very common in congestive heart failure (CHF) and coronary heart disease (CHD) patients. Anemia in CHF and CHD patients is associated with poorer outcomes, including an increased risk of hospitalization, decreased exercise capacity, and poor quality of life. Despite the association with poorer outcomes, it is unclear whether treating anemia or iron deficiency will improve outcomes. Anemia treatment strategies in heart failure and CHD patients include erythropoiesis-stimulating agents (ESAs) and red blood cell transfusions. Iron replacement in iron deficient patients with or without anemia has also been investigated. The objective of this evidence review is to evaluate the balance of benefit and harms of these treatments.Evidence-based synthesis program (Series)Treatment of anemia in patients with heart diseaseAnemiaHeartDiseasesDiagnosisUnited StatesfastTechnical reports.lcgftAnemia.HeartDiseasesDiagnosis.616.152Kansagara Devan1351781United States.Department of Veterans Affairs.Health Services Research and Development Service,Portland VA Medical Center.Evidence-based Synthesis Program Center.Evidence-based Synthesis Program (U.S.)NjHacINjHaclBOOK9910717345703321Treatment of anemia in patients with heart disease3275653UNINA